公开(公告)号：US20130274478A1

公开(公告)日：2013-10-17

申请号：US13912305

申请日：2013-06-07

Applicant: Jagdev Singh JARYAL ,  Swargam SATHYANARAYANA ,  Rajesh Kumar THAPER ,  Mohan PRASAD

Inventor： Jagdev Singh JARYAL ,  Swargam SATHYANARAYANA ,  Rajesh Kumar THAPER ,  Mohan PRASAD

IPC: C07D213/68

CPC classification number: C07D213/68 ,  C07D213/81

Abstract: The present invention provides amorphous and crystalline forms of acid addition salts of sorafenib, pharmaceutical compositions comprising them, and their use for the treatment of cancer. The present invention also provides processes for the preparation of acid addition salts of sorafenib.

Abstract translation: 本发明提供索拉非尼的酸加成盐的无定形和结晶形式，包含它们的药物组合物及其用于治疗癌症的用途。 本发明还提供了制备索拉非尼的酸加成盐的方法。

公开(公告)号：US20130210885A1

公开(公告)日：2013-08-15

申请号：US13575424

申请日：2011-01-28

Applicant: Sudhir Singh Sanwal ,  Saridi Madhava Dileep Kumar ,  Swargam Sathyanarayana ,  Rajesh Kumar Thaper ,  Mohan Prasad

Inventor： Sudhir Singh Sanwal ,  Saridi Madhava Dileep Kumar ,  Swargam Sathyanarayana ,  Rajesh Kumar Thaper ,  Mohan Prasad

IPC: C07D403/06

CPC classification number: C07D403/06

Abstract: The present invention relates to crystalline forms of L-malic acid salt of sunitinib and its preparation. The crystalline forms of the present invention are designated as Form V and Form VI of L-malic acid salt of sunitinib. Formula (I).

Abstract translation: 本发明涉及舒尼替尼的L-苹果酸盐的结晶形式及其制备方法。 本发明的结晶形式称为舒尼替尼的L-苹果酸盐的V型和VI型。 式（I）。

公开(公告)号：US20120190849A1

公开(公告)日：2012-07-26

申请号：US13389358

申请日：2010-08-09

Applicant: Anu Mittal ,  Mahavir Singh Khanna ,  Rajesh Kumar Thaper ,  Mohan Prasad

Inventor： Anu Mittal ,  Mahavir Singh Khanna ,  Rajesh Kumar Thaper ,  Mohan Prasad

IPC: C07D487/04

CPC classification number: C07D487/04 ,  C07D249/12 ,  C07D295/26

Abstract: The present invention provides processes for the preparation of vardenafil, its pharmaceutically acceptable salts, hydrates and intermediates.

Abstract translation: 本发明提供了伐地那非，其药学上可接受的盐，水合物和中间体的制备方法。

公开(公告)号：US08124783B2

公开(公告)日：2012-02-28

申请号：US11813093

申请日：2004-12-30

Applicant: Shailendra Kumar Dubey ,  Amit Kumar Sharma ,  Beena S. Rani ,  Soumendu Paul ,  Rajesh Kumar Thaper ,  Dubey Sushil Kumar ,  Jag Mohan Khanna

Inventor： Shailendra Kumar Dubey ,  Amit Kumar Sharma ,  Beena S. Rani ,  Soumendu Paul ,  Rajesh Kumar Thaper ,  Dubey Sushil Kumar ,  Jag Mohan Khanna

IPC: C07D211/82 ,  C07D211/70

CPC classification number: C07D213/89 ,  C07D211/22

Abstract: Disclosed herein the process for producing 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2yl)methyl]piperidine or its salt thereof employing novel intermediates.

Abstract translation: 本文公开了使用新型中间体生产1-苄基-4 - [（5,6-二甲氧基-1-茚满酮-2-基）甲基]哌啶或其盐的方法。

公开(公告)号：US20110124879A1

公开(公告)日：2011-05-26

申请号：US12674642

申请日：2008-08-06

Applicant: Rajesh Kumar Thaper ,  Manoj Devilalji Prabhavat ,  Yogesh Dadaji Pawar ,  Pritesh R. Upadhyay

Inventor： Rajesh Kumar Thaper ,  Manoj Devilalji Prabhavat ,  Yogesh Dadaji Pawar ,  Pritesh R. Upadhyay

IPC: C07D209/88

CPC classification number: C07D209/88

Abstract: The present invention provides a novel stable amorphous form of carvedilol dihydrogen phosphate and the process for its preparation that involves reaction of carvedilol base with ortho phosphoric acid in the presence of stabilizer in a suitable solvent or mixture of solvents followed by concentration and isolation. An alternate process for preparation of amorphous form of carvedilol dihydrogen phosphate involves addition of stabiliser to the solution of stable amorphous or crystalline carvedilol dihydrogen phosphate in a suitable solvent or mixture of solvents followed by concentration and isolation. The novel stable amorphous form of carvedilol dihydrogen phosphate is highly stable.

Abstract translation: 本发明提供了一种新颖的卡维地洛磷酸二氢不稳定形式及其制备方法，其中包括在稳定剂存在下，在合适的溶剂或溶剂混合物中将卡维地洛碱与原磷酸反应，随后浓缩和分离。 用于制备无定形形式的卡维地洛磷酸二氢盐的替代方法包括在合适的溶剂或溶剂混合物中将稳定剂加入稳定的无定形或结晶卡维地洛二磷酸盐溶液中，然后浓缩和分离。 卡维地洛磷酸二氢盐的新型稳定无定形形式是高度稳定的。

公开(公告)号：US07795451B2

公开(公告)日：2010-09-14

申请号：US11815969

申请日：2006-02-10

Applicant: Bhausaheb Chavhan ,  Arun Kumar Awasthi ,  Richa Aggarwal ,  Rani S. Beena ,  Soumendu Paul ,  Rajesh Kumar Thaper ,  Sushil Kumar Dubey

Inventor： Bhausaheb Chavhan ,  Arun Kumar Awasthi ,  Richa Aggarwal ,  Rani S. Beena ,  Soumendu Paul ,  Rajesh Kumar Thaper ,  Sushil Kumar Dubey

IPC: C07D209/12

CPC classification number: C07D209/10

Abstract: Disclosed herein are novel polymorphic forms of Fluvastatin sodium, wherein said polymorphic forms are designated as JF, JF1, JF2, JF3 and are characterized by their powder X-ray diffraction patterns, Infrared absorption spectrums, thermo gravimetric analysis and differential scanning calorimetry. The processes for preparing said polymorphic forms are also disclosed. The present invention also relates to process for preparing amorphous form of Fluvastatin sodium.

Abstract translation: 本文公开了氟伐他汀钠的新型多晶型物，其中所述多晶型物质命名为JF，JF1，JF2，JF3，其特征在于它们的粉末X射线衍射图，红外吸收光谱，热重分析和差示扫描量热法。 还公开了制备所述多晶型物的方法。 本发明还涉及制备氟伐他汀钠无定形形式的方法。

公开(公告)号：US20080300408A1

公开(公告)日：2008-12-04

申请号：US11718857

申请日：2006-08-21

Applicant: Satish Chandra Pandey ,  Khushi Ram ,  Manoj Kumar Singh ,  Rajesh Kumar Thaper ,  Sushil Kumar Dubey

Inventor： Satish Chandra Pandey ,  Khushi Ram ,  Manoj Kumar Singh ,  Rajesh Kumar Thaper ,  Sushil Kumar Dubey

IPC: C07F9/58

CPC classification number: C07F9/58

Abstract: This process in general relates to the novel process for preparing polymorphic forms of 3-pyridyl-1-hydroxyethylidine-1,1-bisphosphonic acid sodium salt (Risedronate Sodium) in particular risedronate Form A and B employing a solvent system in an appropriate ratio. An improved process for preparation of risedronic acid is also disclosed in the present invention.

Abstract translation: 该方法一般涉及使用适当比例的溶剂体系制备3-吡啶基-1-羟基乙基-1,1-二膦酸钠盐（利塞膦酸钠）的多晶形式的新方法，特别是利塞膦酸盐A和B型。 本发明还公开了改进的利塞膦酸制备方法。

公开(公告)号：US06541511B1

公开(公告)日：2003-04-01

申请号：US10166468

申请日：2002-06-10

Applicant: Rajesh Kumar Thaper ,  Saridi Madhava Dileep Kumar ,  Yatendra Kumar

Inventor： Rajesh Kumar Thaper ,  Saridi Madhava Dileep Kumar ,  Yatendra Kumar

IPC: A61K3135

CPC classification number: C07C69/30 ,  C07C2602/28 ,  C07D309/30

Abstract: The present invention relates to a novel methyl analog of simvastatin, which has the ability to inhibit the synthesis of cholesterol. The compound of the present invention holds promise for the treatment and prophylaxis of hypercholesterolemia and of various cardiac disorders. The invention also relates to a process for making the novel compound.

Abstract translation: 本发明涉及辛伐他汀的新型甲基类似物，其具有抑制胆固醇合成的能力。 本发明的化合物具有治疗和预防高胆固醇血症和各种心脏病的希望。 本发明还涉及制备该新化合物的方法。

公开(公告)号：US06528660B1

公开(公告)日：2003-03-04

申请号：US09979475

申请日：2002-02-12

Applicant: Yatendra Kumar ,  Rajesh Kumar Thaper ,  S. M. Dileep Kumar

Inventor： Yatendra Kumar ,  Rajesh Kumar Thaper ,  S. M. Dileep Kumar

IPC: C07D207327

CPC classification number: C07D207/34

Abstract: A process for the preparation of amorphous atorvastatin calcium and hydrates thereof which comprises: (a) dissolving crystalline atorvastatin calcium in a non-hydroxylic solvent; (b) adding a non-polar hydrocarbon anti-solvent or adding the dissolved atorvastatin to the non-polar anti-solvent to precipitate out atorvastatin calcium; and (c) removing the solvent by filtration to afford amorphous atorvastatin calcium.

公开(公告)号：US08618305B2

公开(公告)日：2013-12-31

申请号：US13575057

申请日：2011-01-28

Applicant: Jagdev Singh Jaryal ,  Swargam Sathyanarayana ,  Rajesh Kumar Thaper ,  Mohan Prasad ,  Sachin Deorao Zade ,  Ajay Shankar Singh

Inventor： Jagdev Singh Jaryal ,  Swargam Sathyanarayana ,  Rajesh Kumar Thaper ,  Mohan Prasad ,  Sachin Deorao Zade ,  Ajay Shankar Singh

IPC: A61K31/44 ,  C07D213/81

CPC classification number: C07D213/81 ,  G01N30/02

Abstract: The present invention provides dimethyl sulphoxide solvate of 4-(4-{3-[4-chloro-3 -(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyridine-2-carboxamide, process for its preparation, pharmaceutical composition comprising it and its use for the treatment of cancer. The present invention also provides a novel HPLC method for the identification, quantification and isolation of related substances of sorafenib.

Abstract translation: 本发明提供4-（4- {3- [4-氯-3-（三氟甲基）苯基]脲基}苯氧基）-N2-甲基吡啶-2-甲酰胺的二甲基亚砜溶剂合物，其制备方法，包含它的药物组合物 并用于治疗癌症。 本发明还提供了用于鉴定，定量和分离索拉非尼相关物质的新型HPLC方法。